METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
1 . A method of treating Rett syndrome comprising administering to a patient diagnosed with Rett syndrome a pharmaceutical composition comprising ganaxolone or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof twice daily.
3 . The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof three times daily.
4 . The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof in an amount of up to 1,800 mg/day.
5 . The method of claim 1 , wherein the pharmaceutical composition is an oral capsule.
6 . The method of claim 1 , wherein the pharmaceutical composition is an oral suspension.
7 . The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof.
8 . The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof and is administered three times daily.
9 . The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof administered three times daily wherein the patient is administered an amount of up to 1,800 mg/day.
10 . The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof.
11 . The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof three times daily.
12 . The method of claim 1 , wherein the patient is administered 50 mg ganaxolone or a pharmaceutically acceptable salt thereof.
13 . The method of claim 1 , wherein the patient is administered 100 mg ganaxolone or a pharmaceutically acceptable salt thereof.
14 . The method of claim 1 , wherein the patient is administered 200 mg ganaxolone or a pharmaceutically acceptable salt thereof.
15 . The method of claim 1 , wherein the patient is administered 300 mg ganaxolone or a pharmaceutically acceptable salt thereof.
16 . The method of claim 1 , wherein the patient is administered 400 mg ganaxolone or a pharmaceutically acceptable salt thereof.
17 . The method of claim 1 , wherein the patient is administered 500 mg ganaxolone or a pharmaceutically acceptable salt thereof.
18 . The method of claim 1 , wherein the patient is administered oral capsules comprising 200-600 mg ganaxolone or a pharmaceutically acceptable salt thereof.
19 . The method of claim 1 , wherein the pharmaceutical composition provides reduction in the frequency of seizures.
20 . The method of claim 1 , wherein the pharmaceutical composition provides reduction in the frequency of seizures, the severity of seizures, or a combination thereof.